Hester Biosciences Ltd 06 Nov 2026 12:00 AM
Hester Biosciences Ltd consolidated sales up 26.76% on year in Q3FY2026,
Hester Biosciences Ltd share price gained 4.34% to Rs 2419.55 after the company`s net profit witnessed a sharp fall of 78.67% to Rs 20.63 crore, while revenue from operations increased sharply by 26.76% to Rs 97.91 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, rising 5.09%. It has marginally improved by 2.18% over last one week and gained upto 2.72% in last one month while the market capitalization of Hester Biosciences Ltd has improved by 5.21% and 0.02% in the same period respectively. Profit before tax (PBT) of Hester Biosciences Ltd stood at Rs 26.45 crore in Q3 FY26, jumping 55.22% year-on-year, and nosediving by 73.99% quarter-on-quarter. EBITDA came in at Rs 31 crore, rallying 1472.22% YoY and expanding by 47.33% sequentially. Total expenses went up by 17.59% to Rs 72.33 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 15.75 crore, advancing by 14.80% YoY, while employee benefits expense was at Rs 15.34 crore, easing 3.09% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 6.91% to Rs 332.6 crore, while net profit saw a strong growth of 99.38% to Rs 57.48 crore, compared to previous TTM. EBITDA jumped by 5821% to Rs 76.98 crore, and PBT jumped 91.66% to Rs 75.84 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 64.14 crore in FY26, as against Rs 64.51 crore in FY25. Hester Biosciences Ltd surged by 51.97% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 4.80% during the same period.
Hester Biosciences Ltd 27 Oct 2026 12:00 AM
Hester Biosciences to review quarterly and half-year financials at board meeting,
Hester Biosciences Limited will hold a board meeting on Thursday, November 5, 2026, to consider the unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2026, as per SEBI regulations.
Hester Biosciences Ltd 14 Oct 2026 12:00 AM
Hester Biosciences reports securities dematerialization confirmation from MUFG Intime India,
Hester Biosciences Limited informed the Bombay Stock Exchange and National Stock Exchange of India that it received a confirmation certificate from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, for the quarter ended September 30, 2026, detailing securities dematerialised and rematerialised as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Hester Biosciences Ltd 06 Oct 2026 12:00 AM
Hester Biosciences invests up to Rs 10.50 million for a 26% stake in SLYCE AGRI WORLD LLP,
Hester Biosciences Limited announced that its board of directors approved a capital contribution of up to Rs 10.50 million for a 26% stake in SLYCE AGRI WORLD LLP, a limited liability partnership incorporated on November 23, 2016, that generates renewable energy. The investment, to be made in one or more tranches, will facilitate a Power Purchase Agreement and enable Hester Biosciences to become a sole captive member consumer of the generating entity, fulfilling captive compliance requirements. SLYCE AGRI WORLD LLP, based in Ahmedabad, reported a turnover of Rs 1.30 million in fiscal year 2022-23, Rs 40.86 million in fiscal year 2023-24, and Rs 22.40 million in fiscal year 2024-25.
Hester Biosciences Ltd 25 Sep 2026 12:00 AM
Hester Biosciences closes equity share trading window ahead of September 2026 results,
Hester Biosciences Limited informed the Bombay Stock Exchange and National Stock Exchange of India that the trading window for dealing in equity shares of the company will be closed from October 1, 2026, and will remain so until 48 hours after the financial results for the quarter and six months ended September 30, 2026, become publicly available.
Subscribe for our
newsletter
Open Account Now